PlumX Metrics
Embed PlumX Metrics

The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials

Asian Journal of Psychiatry, ISSN: 1876-2018, Vol: 24, Page: 53-58
2016
  • 13
    Citations
  • 0
    Usage
  • 65
    Captures
  • 1
    Mentions
  • 5
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    13
  • Captures
    65
  • Mentions
    1
    • News Mentions
      1
      • 1
  • Social Media
    5
    • Shares, Likes & Comments
      5
      • Facebook
        5

Most Recent News

What to know about mixing Strattera and alcohol

Strattera is a medication that a doctor prescribes to treat attention deficit hyperactivity disorder (ADHD). Someone taking Strattera should avoid drinking alcohol. Strattera can help

Article Description

Atomoxetine, a non-stimulant, is FDA approved drug used in the management of adult ADHD. Since the presentation of adult ADHD is different from the childhood onset condition, there is an urgent need to study the efficacy of atomoxetine on the different symptom domains of adult ADHD. To study the efficacy of atomoxetine in treating adult ADHD compared to placebo, we performed a Medline search for English language publications of Randomized Controlled Trials (RCTs) comparing atomoxetine to placebo for adult ADHD using the keywords “adult ADHD”, “atomoxetine” and “placebo”. A total of 41 RCTs were returned of which we included 13 relevant RCTs reporting data on 1824 patients with adult ADHD in the analysis. Standardized mean difference between atomoxetine and placebo for the mean baseline-to-endpoint change in total ADHD scores, impulsivity/hyperactivity and inattention scores was calculated, with a 95% confidence limit. Atomoxetine had superior efficacy than placebo on overall adult ADHD scores [−0.45; 95% CI −0.54, −0.35; overall effect p < 0.00001]. Atomoxetine was superior to placebo on the domains of both inattention [−0.42; 95% CI −0.49, −0.35; overall effect p < 0.00001] and impulsivity/hyperactivity [−0.36; 95% CI −0.44, −0.29; overall effect p < 0.00001]. Atomoxetine was significantly more efficacious (p < 0.00001) in treating inattention than hyperactivity/impulsivity. Atomoxetine is efficacious in treating adult ADHD compared to placebo, though the efficacy is significantly superior for inattention than hyperactivity/impulsivity.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know